Global COPD Partnering 2010 to 2017

Publisher Name :
Date: 01-Apr-2017
No. of pages: 100
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Provides understanding and access to the COPD partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global COPD Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

• Trends in partnering deals

• Top deals by value

• Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Global COPD Partnering Terms and Agreements since 2010 report provides the reader with the following key benefits:

• In-depth understanding of deal trends since 2010

• Access to headline, upfront, milestone and royalty data

• Comprehensive access to multiple deals entered into by the world's biopharma companies since 2010

• Insight into key deal terms included in contracts, where disclosed

• Understand the key deal terms companies have agreed in deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global COPD Partnering 2010 to 2017

Table of Contents
Executive Summary

Chapter 1 - Therapypartnering trends in numbers
Partnering in numbers - by year
Partnering in numbers - most active
Partnering in numbers - by industry sector
Partnering in numbers - by deal type
Partnering in numbers - by technology type
Partnering in numbers - by stage of development

Chapter 2 - Most active dealmakers

Chapter 3 - Partnering deals directory
Partnering deals directory - by company A-Z
Partnering deals directory - by deal value
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - by stage of development
Partnering deals directory - by technology area

Chapter 4 - Partnering deals with a contract document

Chapter 5 - M&A in numbers
M&A in numbers - by year

Chapter 6 - M&A deals directory
M&A deals directory - by company A-Z
M&A deals directory - by deal value

Chapter 7 - Financing in numbers
Financing in numbers - by year
Financing in numbers - by financing type

Chapter 8 - Financing deals directory
Financing deals directory - by company A-Z
Financing deals directory - by deal value
Financing deals directory - by financing type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering

List of Figures

Figure 1: Partnering frequency by year
Figure 2: Partnering most active
Figure 3: Partnering by industry sector
Figure 4: Partnering by deal type
Figure 5: Partnering by technology area
Figure 6: Partnering by stage of development
Figure 7: M&A frequency by year
Figure 8: Financing frequency by year
Figure 9: Financing by type
  • Community Acquired Pneumonia - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 106
    Community Acquired Pneumonia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H2 2017, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape. Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking ......
  • Community Acquired Pneumonia - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, " Community Acquired Pneumonia -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Community Acquired Pneumonia. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Community Acquired Pneumonia. This report provides information on the therapeutic development for Community Acquired Pneumonia, dealing with all the pipeline drugs and comparative analysis at var......
  • Idiopathic Pulmonary Fibrosis - Pipeline Insights, 2017
    Published: 05-Jul-2017        Price: US 2000 Onwards        Pages: 193
    DelveInsight's, "Idiopathic Pulmonary Fibrosis - Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this indication. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research for the treatment of Idiopathic Pulmonary Fibrosis. This report provides information on the therapeutic development for Idiopathic Pulmonary Fibrosis, dealing with all the pipeline drugs. Comparative analysis of drugs a......
  • EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025
    Published: 01-Jul-2017        Price: US 3995 Onwards        Pages: 37
    EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025 Summary Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty in breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke......
  • Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 466
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms incl......
  • Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 254
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lastin......
  • United States Idiopathic Pulmonary Fibrosis Drug Market Report 2017
    Published: 26-Apr-2017        Price: US 3800 Onwards        Pages: 96
    In this report, the United States Idiopathic Pulmonary Fibrosis Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share ......
  • Global Pneumonia Partnering 2010-2017
    Published: 01-Apr-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the pneumonia partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Pneumonia Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value......
  • Global Idiopathic Pulmonary Fibrosis Partnering 2010 to 2017
    Published: 01-Apr-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the idiopathic pulmonary fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Idiopathic Pulmonary Fibrosis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in part......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs